JP6163502B2 - 抗上皮細胞接着分子（ＥｐＣＡＭ）抗体及びその使用方法 - Google Patents

抗上皮細胞接着分子（ＥｐＣＡＭ）抗体及びその使用方法 Download PDF

Info

Publication number
JP6163502B2
JP6163502B2 JP2014560096A JP2014560096A JP6163502B2 JP 6163502 B2 JP6163502 B2 JP 6163502B2 JP 2014560096 A JP2014560096 A JP 2014560096A JP 2014560096 A JP2014560096 A JP 2014560096A JP 6163502 B2 JP6163502 B2 JP 6163502B2
Authority
JP
Japan
Prior art keywords
antibody
epcam
cells
chain variable
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014560096A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015517982A (ja
JP2015517982A5 (enExample
Inventor
チュン ウー，ハン
チュン ウー，ハン
イン リャオ，メイ
イン リャオ，メイ
ウェイ リン，チェン
ウェイ リン，チェン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Academia Sinica
Original Assignee
Academia Sinica
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Academia Sinica filed Critical Academia Sinica
Publication of JP2015517982A publication Critical patent/JP2015517982A/ja
Publication of JP2015517982A5 publication Critical patent/JP2015517982A5/ja
Application granted granted Critical
Publication of JP6163502B2 publication Critical patent/JP6163502B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP2014560096A 2012-03-02 2013-03-01 抗上皮細胞接着分子（ＥｐＣＡＭ）抗体及びその使用方法 Active JP6163502B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261606220P 2012-03-02 2012-03-02
US61/606,220 2012-03-02
PCT/US2013/028667 WO2013131001A1 (en) 2012-03-02 2013-03-01 ANTI-EPITHELIAL CELL ADHESION MOLECULE (EpCAM) ANTIBODIES AND METHODS OF USE THEREOF

Publications (3)

Publication Number Publication Date
JP2015517982A JP2015517982A (ja) 2015-06-25
JP2015517982A5 JP2015517982A5 (enExample) 2016-06-23
JP6163502B2 true JP6163502B2 (ja) 2017-07-12

Family

ID=49083343

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014560096A Active JP6163502B2 (ja) 2012-03-02 2013-03-01 抗上皮細胞接着分子（ＥｐＣＡＭ）抗体及びその使用方法

Country Status (6)

Country Link
US (1) US9187558B2 (enExample)
EP (1) EP2819695B1 (enExample)
JP (1) JP6163502B2 (enExample)
CN (1) CN104168916B (enExample)
TW (1) TWI485161B (enExample)
WO (1) WO2013131001A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013003624A2 (en) 2011-06-29 2013-01-03 Academia Sinica The capture, purification and release of biological substance using a surface coating
EP3126814B1 (en) 2014-04-01 2019-06-12 Academia Sinica Methods and systems for cancer diagnosis and prognosis
WO2017023704A1 (en) * 2015-07-31 2017-02-09 Sutro Biopharma, Inc. ANTI-EpCAM ANTIBODIES, COMPOSITIONS COMPRISING ANTI-EpCAM ANTIBODIES AND METHODS OF MAKING AND USING ANTI-EpCAM ANTIBODIES
AU2016358296B2 (en) * 2015-11-19 2020-05-21 Revitope Limited Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells
US10107726B2 (en) 2016-03-16 2018-10-23 Cellmax, Ltd. Collection of suspended cells using a transferable membrane
KR20190038567A (ko) 2016-07-26 2019-04-08 테사 테라퓨틱스 피티이. 엘티디. 키메라 항원 수용체
JP6433951B2 (ja) * 2016-08-09 2018-12-05 東芝デジタルソリューションズ株式会社 ネットワーク監視装置およびプログラム
US10787499B2 (en) 2017-02-13 2020-09-29 Regents Of The University Of Minnesota EpCAM targeted polypeptides, conjugates thereof, and methods of use thereof
WO2020018964A1 (en) 2018-07-20 2020-01-23 Fred Hutchinson Cancer Research Center Compositions and methods for controlled expression of antigen-specific receptors
WO2020051141A1 (en) * 2018-09-04 2020-03-12 Academia Sinica A medium composition and method for culturing mesenchymal stem cells
MA55305A (fr) * 2019-03-11 2022-01-19 Janssen Biotech Inc Anticorps bispécifiques anti-v béta 17/anti-cd123
AU2020292304B2 (en) * 2019-06-11 2023-03-30 Bioatla, Inc. Conditionally active anti-EpCam antibodies, antibody fragments, their immunoconjugates and uses thereof
BR112022009259A2 (pt) * 2019-11-14 2022-08-02 Academia Sinica Métodos para tratar, inibir ou eliminar um câncer em um indivíduo
CN110950959B (zh) * 2020-02-25 2020-07-03 和铂医药(上海)有限责任公司 靶向EpCAM的抗体及其制备和应用
CN112094350B (zh) * 2020-06-01 2024-01-05 普众发现医药科技(上海)有限公司 可应用于肿瘤细胞捕获的小鼠抗细胞表面糖蛋白cd326的单克隆抗体
EP4190808A4 (en) * 2020-08-19 2024-07-31 Suzhou Immunofoco Biotechnology Co., Ltd. Humanized antibody, chimeric antigen receptor, nucleic acid, vector, cell and use
CA3205465A1 (en) * 2020-12-18 2022-06-23 Bioardis, Llc Epcam binding molecules and uses thereof
TWI754504B (zh) * 2020-12-25 2022-02-01 龍華科技大學 棉花棒棒體之膠體檢測系統及其檢測方法
KR20240026954A (ko) * 2021-06-25 2024-02-29 아카데미아 시니카 상피 세포 부착 분자(epcam) 억제제 및 wnt 억제제와의 조합된 암 요법
KR20240026985A (ko) * 2021-06-25 2024-02-29 아카데미아 시니카 상피 세포 부착 분자(epcam) 억제제 및 간세포 성장 인자 수용체(hgfr) 억제제와의 조합된 암 요법
JP2023069350A (ja) * 2021-11-05 2023-05-18 シスメックス株式会社 抗体の製造方法及び抗体

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI9809391B8 (pt) * 1997-04-14 2021-05-25 Amgen Res Munich Gmbh processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica
EP1242823B1 (en) * 1999-12-27 2007-07-04 Crucell Holland B.V. Selecting library members capable of binding to epitopes
DK1383785T3 (da) * 2001-05-03 2011-05-23 Merck Patent Gmbh Rekombinant tumorspecifikt antistof og anvendelse deraf
US20070122406A1 (en) * 2005-07-08 2007-05-31 Xencor, Inc. Optimized proteins that target Ep-CAM
US20100311954A1 (en) * 2002-03-01 2010-12-09 Xencor, Inc. Optimized Proteins that Target Ep-CAM
US7696320B2 (en) * 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
EP1629275A2 (de) * 2003-06-02 2006-03-01 Igeneon Krebs-Immuntherapie Forschungs- und Entwicklungs-AG Verfahren zur selektion von epitopen zur immuntherapie
US20050180979A1 (en) * 2004-02-13 2005-08-18 Micromet Ag Anti-EpCAM immunoglobulins
US7521195B1 (en) * 2005-07-21 2009-04-21 Celera Corporation Lung disease targets and uses thereof
EP2142570B1 (en) * 2007-04-04 2011-06-15 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Anti-epcam antibody and uses thereof
JP2011193728A (ja) * 2008-07-17 2011-10-06 Murata Mfg Co Ltd ＥｐＣＡＭに結合能を有するペプチド
GB0909904D0 (en) * 2009-06-09 2009-07-22 Affitech As Product
EP2480687B1 (en) * 2009-09-21 2015-01-28 Paul Walfish Methods and compositions for the diagnosis and treatment of thyroid cancer
WO2011079283A1 (en) 2009-12-23 2011-06-30 Bioalliance C.V. Anti-epcam antibodies that induce apoptosis of cancer cells and methods using same
CA2798202A1 (en) * 2010-05-04 2011-11-10 Paul Walfish Method for the diagnosis of epithelial cancers by the detection of ep-icd polypeptide

Also Published As

Publication number Publication date
US9187558B2 (en) 2015-11-17
EP2819695A1 (en) 2015-01-07
CN104168916B (zh) 2017-07-04
JP2015517982A (ja) 2015-06-25
EP2819695A4 (en) 2016-01-20
TWI485161B (zh) 2015-05-21
TW201350507A (zh) 2013-12-16
CN104168916A (zh) 2014-11-26
EP2819695B1 (en) 2018-06-27
US20150017230A1 (en) 2015-01-15
WO2013131001A1 (en) 2013-09-06

Similar Documents

Publication Publication Date Title
JP6163502B2 (ja) 抗上皮細胞接着分子（ＥｐＣＡＭ）抗体及びその使用方法
KR102159773B1 (ko) 글리피칸-3에 대한 고친화력 단클론 항체 및 이의 용도
JP5788384B2 (ja) 形質転換増殖因子アルファに結合し、Ｒａｓ遺伝子変異癌に対して増殖抑制活性を有する抗体
US20090326205A1 (en) ANTI-HUMAN Dlk-1 ANTIBODY SHOWING ANTI-TUMOR ACTIVITY IN VIVO
KR20140006713A (ko) Dll4에 특이적으로 결합하는 신규한 단일클론항체 및 이의 용도
JP6280040B2 (ja) ｉｎｖｉｖｏで抗腫瘍活性を有する抗ヒトＤｌｋ−１抗体
KR102408161B1 (ko) 대상체가 췌관 선암을 앓을 위험을 평가하기 위한 초기 및 비 침습적 방법 및 이러한 질환의 치료 방법
TWI621629B (zh) 用於對抗血管新生及腫瘤標靶治療之對抗第二型血管內皮生長受體之人類抗體
US10829560B2 (en) Agents binding specifically to human cadherin-17, human cadherin-5, human cadherin-6 and human cadherin-20 RGD motif
US20210079099A1 (en) Antibody against alpha-11 integrin and its use
CN113710273B (zh) 通过靶向驻留在癌细胞上的角蛋白14(krt14)的细胞外部分治疗或预防癌症的方法
JP2015133960A (ja) 抗ヒトｃｌｃｐ１抗体とその用途
CN102692500A (zh) Angptl4作为血清学检测肝癌转移的标志物及其应用
US8969530B2 (en) Anti-clathrin heavy chain monoclonal antibody for inhibition of tumor angiogenesis and growth and application thereof
US20200355686A1 (en) Monoclonal antibody for predicting tamoxifen response in breast cancer patients

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160229

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160229

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160506

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170328

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170509

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170602

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170613

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170619

R150 Certificate of patent or registration of utility model

Ref document number: 6163502

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250